AXS-02 (oral zoledronate) + Placebo

Phase 3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Complex Regional Pain Syndrome

Conditions

Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy

Trial Timeline

Jul 1, 2015 → Jan 1, 2019

NCT ID

NCT02504008

About AXS-02 (oral zoledronate) + Placebo

AXS-02 (oral zoledronate) + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Complex Regional Pain Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT02504008. Target conditions include Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy.

What happened to similar drugs?

7 of 18 similar drugs in Complex Regional Pain Syndrome were approved

Approved (7) Terminated (4) Active (9)

✅clarithromycin, rifabutinPfizerApproved

✅Pregabalin + PregabalinPfizerApproved

✅AzithromycinPfizerApproved

✅Azithromycin + Rifabutin/rifampinPfizerApproved

✅vigabatrinLundbeckApproved

✅SabrilLundbeckApproved

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02504008	Phase 3	UNKNOWN	Jul 1, 2015	Jan 1, 2019	Complex Regional Pain Syndrome

Competing Products

20 competing products in Complex Regional Pain Syndrome

See all competitors

Product	Company	Stage	Hype Score
Zonisamide	Eisai	Phase 3	40
Eslicarbazepine acetate + Eslicarbazepine acetate	Sumitomo Pharma	Phase 3	40
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
Zoledronic acid + Placebo	Novartis	Phase 2	31
RAD001 + Placebo	Novartis	Phase 2	35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
everolimus	Novartis	Phase 3	44
ranolazine	Gilead Sciences	Phase 2	35
clarithromycin, rifabutin	Pfizer	Approved	43
Pregabalin + Pregabalin	Pfizer	Approved	35
Pregabalin	Pfizer	Pre-clinical	18
Azithromycin	Pfizer	Approved	43
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	43
Stavudine	Bristol Myers Squibb	Phase 3	40
Zidovudine + Didanosine	Bristol Myers Squibb	Phase 2	35
Haemocomplettan® P + Human albumin (Placebo)	CSL	Phase 2/3	38
BE1116 + FFP	CSL	Phase 3	47
CSL730 + Placebo	CSL	Phase 1	21
vigabatrin	Lundbeck	Approved	32
Sabril	Lundbeck	Approved	40